{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:31:38Z","timestamp":1790746298255,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"ZS Pharma, Inc."},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sodium zirconium cyclosilicate (SZC; formerly ZS-9) is a selective potassium (K+) binder for the treatment of adults with hyperkalaemia. This post hoc analysis of an open-label, single-arm trial (NCT02163499) compared SZC efficacy and safety &amp;gt;12\u2009months among outpatients with hyperkalaemia and Stages 4 and 5 chronic kidney disease (CKD) versus those with Stages 1\u20133 CKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with serum K+ \u22655.1\u2009mmol\/L (measured by point-of-care i-STAT device) received SZC 10\u2009g three times daily for 24\u201372\u2009h until normokalaemia (i-STAT K+ 3.5\u20135.0\u2009mmol\/L) was achieved [correction phase (CP)], followed by once daily SZC 5\u2009g for \u226412\u2009months [maintenance phase (MP)]. Here, patients were stratified by baseline estimated glomerular filtration rate (eGFR &amp;lt;30 or \u226530\u2009mL\/min\/1.73\u2009m2). Study endpoints included percent achieving normokalaemia during CP and MP, mean serum K+ and bicarbonate during MP, and adverse events (AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 751 patients enrolled, 289 (39%), 453 (60%) and 9 (1%) had baseline eGFR values of &amp;lt;30, \u226530\u2009mL\/min\/1.73\u2009m2 or missing, respectively. During the CP, 82% of patients achieved normokalaemia in both eGFR subgroups within 24\u2009h, and 100 and 95% with baseline eGFR &amp;lt;30 and \u226530\u2009mL\/min\/1.73\u2009m2, respectively, within 72\u2009h. Corresponding proportions with normokalaemia during the MP were 82 and 90% at Day 365, respectively. Mean serum K+ reduction from baseline during the CP was sustained throughout the MP and serum bicarbonate increased. AEs during the MP were more common in the eGFR &amp;lt;30 \u226530\u2009mL\/min\/1.73\u2009m2 subgroup.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>SZC corrects hyperkalaemia and maintains normokalaemia among outpatients regardless of the CKD stage.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ndt\/gfz285","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T20:07:38Z","timestamp":1576526858000},"page":"137-150","source":"Crossref","is-referenced-by-count":57,"title":["Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study"],"prefix":"10.1093","volume":"36","author":[{"given":"Simon D","family":"Roger","sequence":"first","affiliation":[{"name":"Renal Research, Gosford, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip T","family":"Lavin","sequence":"additional","affiliation":[{"name":"Boston Biostatistics Research Foundation, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar V","family":"Lerma","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago College of Medicine\/Advocate Christ Medical Center, Oak Lawn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"McCullough","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi, Jackson, MS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce S","family":"Spinowitz","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, New York Presbyterian Queens, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University of G\u00f6ttingen Medical Centre, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA"},{"name":"The George Institute for Global Health, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Zhao","sequence":"additional","affiliation":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[{"name":"Zucker School of Medicine at Hofstra\/Northwell, Great Neck, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K","family":"Packham","sequence":"additional","affiliation":[{"name":"Melbourne Renal Research Group, Department of Medicine, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,6]]},"reference":[{"key":"2020122916295381700_gfz285-B1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2020122916295381700_gfz285-B2","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"2020122916295381700_gfz285-B3","doi-asserted-by":"crossref","DOI":"10.1159\/000490008","article-title":"Dyskalemia in chronic kidney disease: how concerned should we be?","author":"Tandukar","year":"2018","journal-title":"Nephron"},{"key":"2020122916295381700_gfz285-B4","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"2020122916295381700_gfz285-B5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ackd.2017.06.004","article-title":"Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes","volume":"24","author":"Gilligan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"2020122916295381700_gfz285-B6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ki.2011.380","article-title":"Treatment of chronic kidney disease","volume":"81","author":"Turner","year":"2012","journal-title":"Kidney Int"},{"key":"2020122916295381700_gfz285-B7","year":"2018"},{"key":"2020122916295381700_gfz285-B8","year":"2018"},{"key":"2020122916295381700_gfz285-B9","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"2020122916295381700_gfz285-B10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month Phase 3 Study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020122916295381700_gfz285-B11","doi-asserted-by":"crossref","first-page":"e0178104","DOI":"10.1371\/journal.pone.0178104","article-title":"Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications","volume":"12","author":"Chang","year":"2017","journal-title":"PLoS One"},{"key":"2020122916295381700_gfz285-B12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int"},{"key":"2020122916295381700_gfz285-B13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2020122916295381700_gfz285-B14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2020122916295381700_gfz285-B15","article-title":"Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease","author":"Hunt","year":"2018","journal-title":"Clin Kidney J"},{"key":"2020122916295381700_gfz285-B16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1681\/ASN.2014020205","article-title":"Current status of bicarbonate in CKD","volume":"26","author":"Dobre","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020122916295381700_gfz285-B17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2369-15-55","article-title":"Metabolic acidosis and the progression of chronic kidney disease","volume":"15","author":"Chen","year":"2014","journal-title":"BMC Nephrol"},{"key":"2020122916295381700_gfz285-B18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"2020122916295381700_gfz285-B19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3909\/ricm0782","article-title":"Novel agents for the prevention and management of hyperkalemia","volume":"16","author":"McCullough","year":"2015","journal-title":"Rev Cardiovasc Med"},{"key":"2020122916295381700_gfz285-B20","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656566.2015.1066334","article-title":"Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia","volume":"16","author":"Rafique","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2020122916295381700_gfz285-B21","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"2020122916295381700_gfz285-B22","doi-asserted-by":"crossref","first-page":"e183874","DOI":"10.1001\/jamanetworkopen.2018.3874","article-title":"Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease","volume":"1","author":"Garlo","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2020122916295381700_gfz285-B23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000441262","article-title":"Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety","volume":"41","author":"Bomback","year":"2016","journal-title":"Blood Purif"},{"key":"2020122916295381700_gfz285-B24","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"JACC"},{"key":"2020122916295381700_gfz285-B25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2147\/DDDT.S189454","article-title":"Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis","volume":"13","author":"Zeng","year":"2019","journal-title":"Drug Des Devel Ther"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/1\/137\/35253705\/gfz285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/1\/137\/35253705\/gfz285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T16:51:22Z","timestamp":1665247882000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/1\/137\/5728762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,6]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz285","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,2,6]]}}}